ERBB2 and triple-negative breast carcinoma: With adequate treatment, pCR rates are higher for human epidermal growth factor receptor 2-positive (HER2+) and triple-negative breast cancer (TNBC) subtypes compared to the quite low rates for the hormone receptor (HR)-positive/HER2-negative subtype (2).